Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PRT064445: Preliminary Phase II data

Portola said that preliminary data from a double-blind, placebo-controlled, U.S. Phase II trial in healthy volunteers showed that PRT4445 produced "sustained, dose-related reversal" of anticoagulant activity of Eliquis apixaban. There were no serious adverse events reported.

Read the full 361 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers